



## Microbial Antigen Identification and Vaccine Delivery Systems

Guest Editors:

### Dr. Jorge H. Leitão

Instituto Superior Técnico,  
Universidade de Lisboa, Lisboa,  
Portugal

### Dr. Paulo Bettencourt

Centro de Investigação  
Interdisciplinar em Saúde,  
Faculdade de Medicina,  
Universidade Católica  
Portuguesa, 2625-631 Rio de  
Mouro, Portugal

Deadline for manuscript  
submissions:

**closed (31 July 2022)**

### Message from the Guest Editors

Vaccine efficacy and immunogenicity depend on the host, pathogen, and pathogenesis of the disease. The optimization of vaccine efficacy is therefore a requirement of many vaccines, including approved ones.

Key aspects of vaccine design and development involve the identification of the foremost immunogenic determinants of a pathogen and the choice of the best delivery system. Different vaccine delivery systems, using the same antigen, can induce variable outcomes.

In this Special Issue, we invite articles focused on innovative methods for immunogenic determinants identification from microbial pathogens and the optimization of microbial delivery systems to improve vaccine efficacy and immunogenicity. We welcome all types of manuscripts accepted in the journal, with a special focus in immunogenic determinant identification, irrespective of their biochemical nature and antigen presentation. Given that the efficacy of a vaccine antigen depends greatly on the delivery method, this Special Issue will also focus on improving microbial-based delivery systems.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)